European regulators have approved a new biologic treatment, depemokimab, offering a potential breakthrough for individuals grappling with severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The medication, developed by GSK, stands out as the first and only ultra-long-acting biologic for these conditions in the European Union, promising a significant shift in treatment paradigms. This approval marks a step forward in managing complex respiratory diseases, potentially reducing the burden of frequent hospitalizations and improving quality of life for patients.
The decision by the European Commission allows for depemokimab to be used as an add-on maintenance treatment for severe asthma with type 2 inflammation, characterized by elevated eosinophil counts, in adults and adolescents 12 years and older whose asthma remains poorly controlled despite high-dose inhaled corticosteroids and other asthma medications. It’s also indicated as an add-on therapy with intranasal corticosteroids for adults with severe CRSwNP, particularly those who haven’t responded adequately to systemic corticosteroids or surgery. The approval is based on data from Phase III trials, Swift and Anchor, which demonstrated sustained efficacy with a dosing regimen of depemokimab administered just twice a year.
A New Approach to Managing Severe Asthma and CRSwNP
Cristiano Caruso, Director of the Allergology and Clinical Immunology Unit at the Fondazione Policlinico A. Gemelli IRCCS in Rome – Catholic University of the Sacred Heart, highlighted the significance of depemokimab’s ultra-long-acting nature. “The studies have demonstrated a statistically significant reduction in both severe and moderate exacerbations in patients with severe asthma, with and without comorbidities,” Caruso stated. “We also observed a reduction in hospitalizations and emergency room visits.” He emphasized that the drug represents a pioneering therapy designed to modify the long-term course of the disease, simultaneously addressing related conditions.
The ability to treat both asthma and CRSwNP with a single medication is a key advantage, according to Caruso. “Having a drug that is already approved for dual indication means we can treat a large population of patients in an integrated way, responding to a clinical necessitate that has, until now, been only partially met,” he explained. Approximately 3 million people in Europe suffer from severe asthma, and around 60% of these patients also experience chronic rhinosinusitis with nasal polyps, according to data from the Severe Asthma Network Italy, of which Caruso is a member. This comorbidity significantly contributes to exacerbations and re-hospitalizations.
How Depemokimab Works and its Potential Impact
Depemokimab’s effectiveness stems from its targeted action on interleukin-5 (IL-5), a key cytokine involved in eosinophilic inflammation, a hallmark of both asthma and CRSwNP. “Interleukin 5 is extremely essential in both asthma and nasal polyposis, because it is the cytokine that essentially supports eosinophilic inflammation,” Caruso clarified. By blocking this pathway, the drug intervenes at a fundamental level of the disease process in eligible patients. The drug is described as more potent than previous anti-interleukin-5 therapies, with biochemical characteristics that allow for its extended duration of action.
The clinical trials, including Swift 1 and Swift 2, also included an open-label extension study lasting an additional 12 months. This extension confirmed not only the treatment’s efficacy and safety but also suggested a potential cumulative effect, with progressive improvements over time. In trials evaluating the drug’s impact on CRSwNP, specifically the Anchor trial, researchers assessed parameters like the Nasal Polyp Score, which measures the extent of polyps endoscopically. Results showed a statistically significant reduction in the score compared to placebo. The treatment demonstrated a reduction in the need for oral corticosteroids and limited the need for further surgical interventions, suggesting a disease-modifying effect in both patients with and without associated asthma.
Beyond Asthma and CRSwNP: Exploring Further Applications
Research is ongoing to evaluate depemokimab’s potential in other conditions characterized by eosinophilic inflammation. The drug is currently in Phase III trials for granulomatosis with polyangiitis and hypereosinophilic syndromes. “The goal is to build a therapeutic strategy capable of comprehensively covering all pathologies sustained by type 2 inflammation with high levels of eosinophils and interleukin 5,” Caruso noted. This broader approach could potentially benefit a wider range of patients suffering from inflammatory diseases.
The long dosing interval – every six months – is expected to significantly improve treatment adherence and quality of life. “A less frequent therapy facilitates the patient’s journey, reduces the care burden, and contributes to improving quality of life, which remains one of the main objectives in managing chronic diseases,” explained Giorgio Walter Canonica, Professor and Senior Consultant at the Center for Personalized Medicine Asthma and Allergies, Humanitas University & IRCCS Clinical Research Institute in Milan, in a separate statement. Canonica further emphasized that the simplified regimen enhances sustainability by promoting adherence, reducing management costs, and maintaining clinical efficacy.
The European approval of depemokimab represents a significant advancement in the treatment of severe asthma and CRSwNP, offering a new hope for patients seeking long-term relief and improved disease control. Further research will continue to explore the drug’s potential in other inflammatory conditions, potentially expanding its impact on a broader range of patients. The next step involves monitoring real-world outcomes and gathering further data on the long-term effects of depemokimab as it becomes more widely available to patients across Europe.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have thoughts on this new treatment option? Share your comments below, and please share this article with anyone who might find it helpful.
